XML 111 R64.htm IDEA: XBRL DOCUMENT v3.20.4
Debt - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
May 31, 2020
Dec. 31, 2019
Nov. 30, 2019
Oct. 31, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Debt Instrument [Line Items]              
Line of credit       $ 40,000,000      
Loss on extinguishment of debt           $ 4,877,000 $ 2,857,000
Maturity date           Oct. 11, 2024  
Debt issuance costs and discounts           $ 600,000  
Amortization of debt issuance costs and discounts         $ 3,000,000 $ 3,300,000 $ 800,000
Line of credit facility extended period           1 year  
Line of credit fixed fronting fee percentage         0.125%    
Principal balance   $ 0     $ 0 $ 0  
Decrease of letter of credit   900,000          
Increase in line of credit amount $ 60,000,000            
Letter of Credit              
Debt Instrument [Line Items]              
Principal balance   9,100,000     9,100,000 9,100,000  
Letter of Credit | New Facility Lease              
Debt Instrument [Line Items]              
Principal balance   $ 9,000,000       $ 9,000,000  
Revolving Credit Facility              
Debt Instrument [Line Items]              
Proceeds from line of credit         28,000,000    
Repayments of line of credit         $ 28,000,000    
First Lien Credit Agreement              
Debt Instrument [Line Items]              
Line of credit 100,000,000   $ 155,000,000 545,000,000      
Effective interest rate   5.90%     3.97% 5.90%  
Frequency of interest payment         quarterly    
Maturity date         Oct. 10, 2025    
Description of payments         The First Lien requires quarterly principal payments from March 2019 through September 2025, with any remaining unpaid principal and any accrued and unpaid interest due on the maturity date of October 10, 2025.    
Covenant terms         As of December 31, 2020, the Company is subject to a financial covenant requiring maintenance of a Net Leverage Ratio not to exceed 8.2 to 1.0 and other nonfinancial covenants under the First Lien. Additionally, GoodRx is restricted from making dividend payments, loans or advances to the Company. At December 31, 2020, the Company was in compliance with its covenants.    
Maximum net leverage ratio         8.20%    
First Lien Credit Agreement | Other Assets              
Debt Instrument [Line Items]              
Deferred Finance Costs Net $ 1,300,000            
First Lien Credit Agreement | GoodRx, Inc.              
Debt Instrument [Line Items]              
Percentage of collateralized assets         100.00%    
First Lien Credit Agreement | Minimum              
Debt Instrument [Line Items]              
Interest rate on used amounts         2.75%    
Interest rate on used amounts           2.50%  
Interest rate on unused amounts           0.25%  
First Lien Credit Agreement | Maximum              
Debt Instrument [Line Items]              
Interest rate on used amounts         3.00%    
Interest rate on used amounts           3.00%  
Interest rate on unused amounts           0.50%  
First Lien Credit Agreement | Other Expense, Net              
Debt Instrument [Line Items]              
Debt third-party costs     2,900,000        
Second Lien Credit Agreement              
Debt Instrument [Line Items]              
Line of credit       $ 200,000,000      
Interest rate on used amounts       7.50%      
Loss on extinguishment of debt     $ 4,900,000